13 completed, 3 terminated, 1 withdrawn. 9 Phase 1, 9 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 8, Withdrawn 1 |
| Phase 2 | 9 | Completed 7, Terminated 2 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow Rigosertib: new trials by email Literature Review of Rigosertib trials Research Report on Rigosertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors Rigosertib, Pembrolizumab, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 7 | 2023-05-09 | 2026-09-16 |
| Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment Rigosertib, Nivolumab - Non-small Cell Lung Cancer, Adenocarcinoma | Phase 1 / Phase 2 | Completed | Icahn School of Medicine at Mount Sinai | 25 | 2020-06-29 | 2024-05-09 |
| Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia Rigosertib, Questionnaire - Leukemia, Myelofibrosis | Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2017-08-16 | 2020-08-07 |
| Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA rigosertib, Any approved or standard-of-care therapy, best supportive care (BSC) - Myelodysplastic Syndrome, MDS | Phase 3 | Terminated | Traws Pharma, Inc. | 372 | 2015-12-02 | 2022-09-26 |
| Three Dosing Schedules of Oral Rigosertib in MDS Patients rigosertib - Myelodysplastic Syndrome | Phase 1 | Withdrawn | Traws Pharma, Inc. | 2014-05-01 | 2020-07-01 | |
| Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers rigosertib - Healthy | Phase 1 | Completed | Traws Pharma, Inc. | 6 | 2014-01-01 | 2017-06-23 |
| Oral Rigosertib for Squamous Cell Carcinoma rigosertib - Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma | Phase 2 | Completed | Traws Pharma, Inc. | 64 | 2013-03-01 | 2017-06-26 |
| Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome rigosertib - Myelodysplastic Syndrome, MDS | Phase 2 | Completed | Traws Pharma, Inc. | 82 | 2012-05-01 | 2017-06-26 |
| Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts ON 01910.Na - Myelodysplastic Syndromes, MDS | Phase 3 | Completed | Traws Pharma, Inc. | 299 | 2010-11-01 | 2020-06-30 |
| Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors rigosertib - Solid Tumor | Phase 1 | Completed | Traws Pharma, Inc. | 68 | 2010-07-01 | 2017-06-23 |
| Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) rigosertib - Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Traws Pharma, Inc. | 30 | 2010-07-01 | 2017-06-26 |
| Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome ON 01910.Na - Myelodysplastic Syndrome | Phase 1 | Completed | Traws Pharma, Inc. | 36 | 2009-12-01 | 2017-06-23 |
| Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk ON 01910.Na - Myelodysplastic Syndrome | Phase 2 | Completed | Traws Pharma, Inc. | 14 | 2009-05-01 | 2017-06-26 |
| Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients ON 01910.Na - Ovarian Cancer | Phase 2 | Completed | Traws Pharma, Inc. | 1 | 2009-03-01 | 2017-07-21 |
| Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML ON 01910.Na - Myelodysplastic Syndrome, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Traws Pharma, Inc. | 36 | 2009-01-01 | 2017-06-26 |
| Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer rigosertib sodium - Advanced Cancer, Solid Tumors | Phase 1 | Completed | Traws Pharma, Inc. | 29 | 2006-08-01 | 2017-06-23 |
| Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer rigosertib sodium - Solid Tumors, Advanced Cancer | Phase 1 | Completed | Traws Pharma, Inc. | 42 | 2006-06-01 | 2017-06-23 |
Myelodysplastic Syndromes (7) · Neoplasms (3) · Anemia, Refractory, with Excess of Blasts (2) · Chromosome 8, trisomy (2) · Leukemia, Myeloid, Acute (2) · Primary Myelofibrosis (2) · Adenocarcinoma (1) · Anemia (1) · Anemia, Refractory (1) · Anus Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Squamous Cell (1) · Cytopenia (1) · Esophageal Squamous Cell Carcinoma (1) · Head and Neck Neoplasms (1)
Traws Pharma, Inc. (14) · Icahn School of Medicine at Mount Sinai (1) · M.D. Anderson Cancer Center (1) · Vanderbilt-Ingram Cancer Center (1)
United States (17) · Belgium (2) · France (2) · Germany (2) · Italy (2) · Spain (2) · Australia (1) · Austria (1) · Canada (1) · Croatia (1) · Czechia (1) · Estonia (1) · Hungary (1) · India (1) · Ireland (1)
Steven M. Fruchtman, MD (3) · Azra Raza, MD (2) · Jorge Cortes, MD (2) · Antonio Jimeno, MD, PhD (1) · Douglas Johnson, MD (1) · Francois Wilhelm, MD, PhD (1) · Gregory P. Sutton, MD (1) · Mark Heaney, MD (1) · Michael Kurman, MD (1) · Peter L. Greenberg, MD (1) · Rajwanth Veluswamy, MD, MSCR (1) · Rami Komrokji, MD (1) · Sridhar Mani, MD (1) · Takao Ohnuma, MD (1)
PMID 27400247, PMID 21924492, PMID 23841031, PMID 24777753, PMID 26968357
2015 (1)